MEDIA
Recent Press Releases
December 13, 2011
Intarcia and Quintiles Finalize Innovative Alliance to Advance Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
October 21, 2011
Intarcia and Quintiles Sign Letter of Intent for Innovative Global Collaboration to Advance ITCA 650 in Type 2 Diabetes
September 14 , 2011
Intarcia Presents Positive 48-week Results from Phase 2 Study of ITCA 650 at the 47th Annual Meeting of the European Association for the Study of Diabetes
June 28 , 2011
Intarcia Presents Positive Phase 2 48-week Results from ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions
September 22, 2010
Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD
September 16, 2010
Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals
Pipeline
Learn more about ITCA 650: Intarcia's clinical stage type 2 diabetes candidate involves the delivery of exenatide, an approved incretin mimetic, with the subcutaneous DUROS delivery device.
